search
Back to results

Antistax® in Patients With Chronic Venous Insufficiency

Primary Purpose

Venous Insufficiency

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Antistax®, low dose
Antistax®, high dose
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Venous Insufficiency

Eligibility Criteria

25 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female
  • Between 25 and 75 years of age
  • CVI I or CVI II (without expanded trophic disturbances)
  • Willing and able to give written informed consent prior to participation in the study

Exclusion Criteria:

Concomitant disease(s) exclusion criteria:

  • Decompensated cardiac insufficiency
  • Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
  • Peripheral arterial disease (ankle/arm pressure index < 0.9)
  • Current acute phlebitis or thrombosis
  • Renal insufficiency (Serum creatinine > 1.5 mg/dl)
  • Liver disease (SGPT (ALAT) > 3x upper limit of normal)
  • Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
  • Anamnestic indications of diabetic microangiopathy or polyneuropathy
  • Drug and/or alcohol abuse
  • Severe climacteric complaints
  • Immobility
  • Avalvulia
  • Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
  • State after pulmonary embolism
  • Recognized hypersensitivity to the trial drug ingredients
  • Current florid venous ulcus
  • Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.

Previous treatment(s) exclusion criteria:

  • Treatment with venous drugs within the last 4 weeks
  • Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days
  • Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
  • Changes in post-menopausal Hormone replacement within the last 2 months

Concomitant treatment/non-drug therapy exclusion criteria:

  • Other venous drugs apart from the trial medication
  • Compression therapy
  • Venous surgery at the leg(s)
  • Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
  • Major surgery requiring full anesthesia

Other exclusion criteria:

  • Previously studied under this protocol
  • Participation in another clinical trial within the previous 90 days or during the present study
  • Patients who have visited a sauna or had other thermal applications in the previous day before any visit
  • Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
  • Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
  • Patients in a bad general health state according to the investigator's judgment

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    Antistax®, low dose

    Antistax®, high dose

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Changes from baseline of limb volume
    determined by water displacement

    Secondary Outcome Measures

    Changes of limb volume
    determined by water displacement
    Measurement of calf circumference
    in centimeters
    Measurement of ankle circumference
    in centimeters
    Assessment of subjective symptoms on a visual analogue scale (VAS)
    Assessment of global efficacy by patient on a 4-point verbal rating scale
    Assessment of global efficacy by investigator on a 4-point verbal rating scale
    Assessment of global tolerability by patient on a 4-point verbal rating scale
    Assessment of global tolerability by investigator on a 4-point verbal rating scale
    Number of patients with adverse events

    Full Information

    First Posted
    July 15, 2014
    Last Updated
    July 15, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02191280
    Brief Title
    Antistax® in Patients With Chronic Venous Insufficiency
    Official Title
    The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    April 1998 (undefined)
    Primary Completion Date
    September 1998 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Venous Insufficiency

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    260 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Antistax®, low dose
    Arm Type
    Experimental
    Arm Title
    Antistax®, high dose
    Arm Type
    Experimental
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Antistax®, low dose
    Intervention Type
    Drug
    Intervention Name(s)
    Antistax®, high dose
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Changes from baseline of limb volume
    Description
    determined by water displacement
    Time Frame
    Baseline, day 84
    Secondary Outcome Measure Information:
    Title
    Changes of limb volume
    Description
    determined by water displacement
    Time Frame
    Baseline, days 42 and 98
    Title
    Measurement of calf circumference
    Description
    in centimeters
    Time Frame
    Baseline, days 42, 84 and 98
    Title
    Measurement of ankle circumference
    Description
    in centimeters
    Time Frame
    Baseline, days 42, 84 and 98
    Title
    Assessment of subjective symptoms on a visual analogue scale (VAS)
    Time Frame
    Baseline, days 42, 84 and 98
    Title
    Assessment of global efficacy by patient on a 4-point verbal rating scale
    Time Frame
    days 42, 84 and 98
    Title
    Assessment of global efficacy by investigator on a 4-point verbal rating scale
    Time Frame
    days 42, 84 and 98
    Title
    Assessment of global tolerability by patient on a 4-point verbal rating scale
    Time Frame
    days 42, 84 and 98
    Title
    Assessment of global tolerability by investigator on a 4-point verbal rating scale
    Time Frame
    days 42, 84 and 98
    Title
    Number of patients with adverse events
    Time Frame
    up to 14 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    25 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female Between 25 and 75 years of age CVI I or CVI II (without expanded trophic disturbances) Willing and able to give written informed consent prior to participation in the study Exclusion Criteria: Concomitant disease(s) exclusion criteria: Decompensated cardiac insufficiency Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc) Peripheral arterial disease (ankle/arm pressure index < 0.9) Current acute phlebitis or thrombosis Renal insufficiency (Serum creatinine > 1.5 mg/dl) Liver disease (SGPT (ALAT) > 3x upper limit of normal) Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies Anamnestic indications of diabetic microangiopathy or polyneuropathy Drug and/or alcohol abuse Severe climacteric complaints Immobility Avalvulia Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans) State after pulmonary embolism Recognized hypersensitivity to the trial drug ingredients Current florid venous ulcus Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc. Previous treatment(s) exclusion criteria: Treatment with venous drugs within the last 4 weeks Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days Changes in post-menopausal Hormone replacement within the last 2 months Concomitant treatment/non-drug therapy exclusion criteria: Other venous drugs apart from the trial medication Compression therapy Venous surgery at the leg(s) Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance Major surgery requiring full anesthesia Other exclusion criteria: Previously studied under this protocol Participation in another clinical trial within the previous 90 days or during the present study Patients who have visited a sauna or had other thermal applications in the previous day before any visit Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only) Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial Patients in a bad general health state according to the investigator's judgment

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    33141449
    Citation
    Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4.
    Results Reference
    derived
    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1138/1138.2_U99-0196.pdf
    Description
    Related Info

    Learn more about this trial

    Antistax® in Patients With Chronic Venous Insufficiency

    We'll reach out to this number within 24 hrs